Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma.
Dall'Ora M, Rovesti G, Reggiani Bonetti L, Casari G, Banchelli F, Fabbiani L, Veronesi E, Petrachi T, Magistri P, Di Benedetto F, Spallanzani A, Chiavelli C, Spano MC, Maiorana A, Dominici M, Grisendi G. Dall'Ora M, et al. Among authors: spallanzani a. Am J Cancer Res. 2021 Sep 15;11(9):4500-4514. eCollection 2021. Am J Cancer Res. 2021. PMID: 34659901 Free PMC article.
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study).
Gelsomino F, Bertolini F, Luppi G, Spallanzani A, Pettorelli E, Reggiani Bonetti L, Meduri B, Manco G, Conte P, Cascinu S. Gelsomino F, et al. Among authors: spallanzani a. Clin Colorectal Cancer. 2017 Dec;16(4):410-415.e1. doi: 10.1016/j.clcc.2017.03.011. Epub 2017 Mar 24. Clin Colorectal Cancer. 2017. PMID: 28410832 Clinical Trial.
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
Salati M, Caputo F, Cunningham D, Marcheselli L, Spallanzani A, Rimini M, Gelsomino F, Reggiani-Bonetti L, Andrikou K, Rovinelli F, Smyth E, Baratelli C, Kouvelakis K, Kalaitzaki R, Gillbanks A, Michalarea V, Cascinu S, Braconi C. Salati M, et al. Among authors: spallanzani a. Eur J Cancer. 2019 Aug;117:84-90. doi: 10.1016/j.ejca.2019.05.030. Epub 2019 Jul 2. Eur J Cancer. 2019. PMID: 31276980 Free article.
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Casadei-Gardini A, et al. Among authors: spallanzani a. Clin Colorectal Cancer. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001. Epub 2020 Mar 17. Clin Colorectal Cancer. 2020. PMID: 32192883
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
Salati M, Rizzo A, Merz V, Messina C, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, Melisi D, Brandi G, Dominici M. Salati M, et al. Among authors: spallanzani a. Expert Rev Gastroenterol Hepatol. 2022 Jan;16(1):73-79. doi: 10.1080/17474124.2022.2017772. Epub 2021 Dec 21. Expert Rev Gastroenterol Hepatol. 2022. PMID: 34890512
Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy.
Salati M, Marcheselli L, Messina C, Merz V, Messina M, Carotenuto P, Caputo F, Gelsomino F, Spallanzani A, Reggiani Bonetti L, Caramaschi S, Luppi G, Dominici M, Ghidini M. Salati M, et al. Among authors: spallanzani a. Cancer Manag Res. 2022 Mar 5;14:983-993. doi: 10.2147/CMAR.S346235. eCollection 2022. Cancer Manag Res. 2022. PMID: 35283642 Free PMC article.
91 results